Auryxia Approval History
- FDA approved: Yes (First approved September 5th, 2014)
- Brand name: Auryxia
- Generic name: ferric citrate
- Dosage form: Tablets
- Company: Keryx Biopharmaceuticals, Inc.
- Treatment for: Hyperphosphatemia of Renal Failure, Anemia Associated with Chronic Renal Failure
Auryxia (ferric citrate) is a phosphate binder indicated for the control of serum phosphorus levels in dialysis patients; and an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease who are not on dialysis.
Development History and FDA Approval Process for Auryxia
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.